Schizophrenia & Psychotic Disorders

When assessing the value of a reward, people with schizophrenia have difficulty integrating information about the size of the reward and the probability of receiving it, according to a published study.

Articles

A new psychotropic drug for treating adults with schizophrenia met its primary endpoint and was "generally well tolerated" in a phase 2a study, according to its developers.

Popular topics of the year included future opportunities in the treatment of the disease, new medications, and the role of inflammation. 

Anticipate some significant changes in the treatment of schizophrenia over the next 10 years, from a move toward coordinated specialty care to harnessing the power of social media to help identify symptoms sooner, said John M. Kane, MD.

High-dose antipsychotic use in children and young adults without psychosis is associated with an increased risk of unexpected death, according to a study published online in JAMA Psychiatry.

A nationwide study in Denmark suggests a link between infections in childhood and adolescence and increased risk of subsequent mental disorders.

Pages

Blogs

Question:

"Does schizophrenia cause inflammatory changes in the brain?"

Question:

“Is it true that schizophrenia and major depressive disorder have shared genetic underpinning?"

Pages

Posters

Christoph Correll, MD; Steven Potkin, MD; Suresh Durgam, MD; Cheng-Tao Chang, PhD; Balázs Szatmári, MD; István Laszlovszky, PharmD, PhD; Willie Earley, MD; Severus Tomescu, MD, MHA
Stanley Caroff, MD; Fan Mu, PhD; Rajeev Ayyagari, PhD; Traci Schilling, MD; Victor Abler, DO; Benjamin Carroll, PharmD
Benjamin Carroll, PharmD; Paul Juneau, MS; Debra Irwin, MD, MSPH
Gordon Loewen, PhD; Rosa Luo, EM; Evan Smith, BS; Grace Liang, PhD; Khodayar Farahmand, PharmD; Haig Bozigian, PhD; Christopher OкBrien, MD
Hubert Fernandez, MD; Mat Davis, PhD; Stewart Factor, DO; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Karen Anderson, MD

Pages

Video

Joseph P. McEvoy, MD, discusses how cannabis affects the risk of schizophrenia and the course of the disease. Dr. McEvoy is Professor of Psychiatry and Health Behavior and the I. Clark Case Chair in Psychotic Disorders at the Medical College of Georgia.

Psych Congress steering committee member Rakesh Jain, MD, MPH, discussed how to talk to patients with schizophrenia about using long-acting injectable treatments, as part of a presentation at the Psych Congress 1-Day Regional Meeting in Milwaukee. 

Psych Congress steering committee member Rakesh Jain, MD, MPH, discussed the advantages of treating patients with schizophrenia with long-acting injectable treatments, as part of a presentation at the Psych Congress 1-Day Regional Meeting in Milwaukee.

Pages